Navigation Links
Vion Reports 2007 Third Quarter and Nine-Month Results
Date:11/7/2007

M), including additional personnel, drug production costs and other costs in support of a potential registration filing; (ii) stock-based compensation expense; and (iii) a gift to support research projects at a Yale University laboratory, partially offset by lower spending on preclinical drug production. In addition, marketing, general and administrative expenses were higher than the prior year period, primarily due to increased stock-based compensation expense, medical advisory board meetings and patent fees.

The Company reported $1.2 million and $3.4 million of stock-based compensation expense in the three-month and nine-month periods ended September 30, 2007, respectively, as compared to $413,000 and $1.4 million for the comparable 2006 periods.

The Company reported $3.7 million in interest expense for the nine months ended September 30, 2007 related to its private placement in February 2007 of convertible debt and warrants. There was no interest expense in 2006. Interest income increased from $1.6 million for the nine-month period ended September 30, 2006 to $2.6 million for the comparable 2007 period based on higher invested balances and higher interest rates in 2007.

The Company reported ending the quarter with $68.0 million in cash and cash equivalents. Based on its current operating plan, the Company reported that it had funds to operate the Company into the third quarter of 2009 excluding any expenses for commercialization of Cloretazine(R) (VNP40101M) in the United States. If the Company does commercialize Cloretazine(R) (VNP40101M) in the United States on its own, it would have to raise additional capital.

In August, the Company announced that it had completed the initial target accrual of 85 patients for its pivotal Phase II trial of Cloretazine(R) (VNP40101M) as a single agent in elderly de novo poor-risk acute myelogenous leukemia (AML). Recent FDA/ICH guidance recommends that an electrocardiograph evaluation (QT/QTc) study be i
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Involution Studios , a software ... industry's most pressing problems, has launched three open ... Involution Studios' creative team has been on the ... clients including AstraZeneca, 3M Health Information Systems, Partners ... studio's philosophy to change healthcare in a positive ...
(Date:8/28/2014)... 28, 2014 Starting on Monday, the ... able to accept donations in Bitcoin, in addition to ... page can be found at http://www.curemeso.org/bitcoin . ... as a form of payment, we decided it was ... Foundation’s chief executive officer, Melinda Kotzian. , Bitcoin ...
(Date:8/28/2014)... (PRWEB) August 29, 2014 Recently, Skmen.com, ... women’s clothes, has revealed its unique collection of ... promotion. At the moment, all the company’s newly unveiled ... 29 percent off. , As a matter of ... its business growth in the recent years. The company’s ...
(Date:8/28/2014)... The Global and China Oscilloscope Industry is ... of the Oscilloscope industry in Global and China. , ... including definitions, applications and industry chain structure. Global market ... a focus on history, developments, trends and competitive landscape ... Chinese situation is also offered. , The report also ...
(Date:8/28/2014)... HORNE LLP has laid out the challenge to ... million firm has more than feel-good emotions at stake, ... balance. , Described by experts in the accounting industry ... Boomers creating succession issues, poor leadership development strategies, new ... wars within firms that are threatening the life of ...
Breaking Medicine News(10 mins):Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 3Health News:Cancer Research Funding Organization Now Accepts Bitcoin Donations 2Health News:Skmen.com: Bestselling Long Sleeve Sweater Dresses Are Offered Online Now 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:HORNE LLP Proclaims War on Accounting Firm Culture 2
... Based on finding of a recent study researchers say ... day is an effective preventive // measure for people ... anti-epileptic drug. Studies have also shown its success in ... neuralgia, and migraine headache. Since gabapentin often reduces migraines ...
... study reports that kids with asthma are more likely to ... moving or family relationships. // ,60 children who had ... had a history of chronic stress. Over 18 months, kids ... flow tests, which measured their breathing strength. Both kids and ...
... do much to relieve knee pain associated with osteoarthritis, ... studies comparing the drugs to placebos. ,The ... and around 3,000 received placebos. The average age of ... been experiencing symptoms for about eight years. Since long-term ...
... fatigue but can also be dangerous. In some cases ... hours can cause deep-vein thrombosis, a potentially serious condition ... pelvic veins. , ,The risk is greatest for ... cardiovascular disease, cancer and blood-clotting disorders, according to the ...
... could lead to an enlarged heart by early adulthood, ... .// ,Researchers followed 467 children for almost ... participants at childhood with data obtained at young adulthood. ... size. Participants who had the highest BMI levels in ...
... who take high doses of steroids are more than twice ... not, say researchers based on findings of a recent study. ... the skin, lungs, joints, digestive tract, such as asthma, inflammatory ... health records of 68,781 people who used steroids between 1993 ...
Cached Medicine News:
(Date:8/28/2014)... CASTLE ROCK, Colo. , Aug. 28, 2014 /PRNewswire/ ... diagnostic company focused on obtaining FDA clearance for ... a rapid blood test for aiding in identifying children, ... who are at low risk for appendicitis, today announced ... Rodman & Renshaw 16 th Annual Global Investment ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... DUBLIN, Ohio , Aug. 28, 2014 /PRNewswire/ ... rising competition in generics are adding pressure to ... internal resources. Company resources continue to shrink and ... complex. This has led companies to look for ... to commercialization and for keeping approved products on ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 44 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: